Inter-molecular interactions between two smooth muscle myosin heads have been observed using chemical cross linking and visualized by electron microscopy. In order to probe the nature of the phosphorylation-dependent head-head interactions, we performed Hydrogen-Deuterium exchange electrospray ionization mass spectrometry (HDX-MS) on phosphorylated and unphosphorylated smooth muscle heavy mero myosin (HMM) from chicken gizzard. HDX rates are determined by solvent accesibility and the strength of hydrogen bonding and thus are a good fingerprint of intra-and intermolecular structural changes. The observed decrease in deuterium uptake upon phosphorylation in the coiledcoil and the hinge region of the heavy chain (residues 864-877), is consistent with the unraveling of the myosin dimer at the hinge. Unexpectedly, we have observed phosphorylation dependent changes in the regulatory light chain (RLC 58-69), which are not implicated in the RLC-RLC or RLC-heavy chain interface. No changes were observed for N-terminal region of RLC that was postulated to undergo major secondary structure changes, or in the heavy chain actin binding site (residues 397-437) , or any of the residues that form the headhead interface in the EM model of Wendt & Taylor. This latter finding indicates that the interaction between the heads is probably transient in solution, or in the unlikely case, interacting heads constitute a very small fraction of total protein. Hoshi University, Tokyo, Japan. Smooth muscle is distributed in many organs, and plays a critical role in maintaining blood pressure in vasculature and airflow in airway and malfunction of the smooth muscle causes severe health problems. Smooth muscle contraction is primarily regulated by myosin light chain (MLC) phosphorylation, which is regulated by both Ca 2þ dependent and Ca 2þ independent pathways. Recent studies have revealed that MLC phosphatase (MLCP) plays a key role in the latter mechanism. MLCP activity is regulated by the phosphorylation of MYPT1, a myosin binding regulatory subunit of MLCP, and CPI-17, a MLCP specific inhibitor protein. Here we found novel signaling mechanism of controlling smooth muscle contraction induced by agonists. We found that agonist stimulation significantly activates Rac1 activity in smooth muscle, and the inhibition of Rac markedly decreases agonist induced force of arterial smooth muscle. Moreover, introduction of active Rac1 activates smooth muscle contraction, while dominant-negative Rac1 attenuates the agonist-induced contraction. Rac1 dependent change in contraction is accompanied by the change in MLC phosphorylation, MYPT1 phosphorylation and CPI-17 hosphorylation. Rac inhibitors activated MLCP activity, but not MLCK activity, suggesting that Rac1 dependent change in MLC phosphorylation is due to the change in MLCP activity. Rac inhibitors did not change RhoA and ROCK activities, unlike RhoA pathway. Interestingly, Rac1 inhibition induced the change in MYPT1/CPI-17 phosphatase activity. The result suggests that Rac1 dependent change in MYPT1/CPI-17 phosphorylation is due to the change in the phosphatase activity rather than the kinase activites that phopshorylate MYPT1 and CPI-17 such as ROCK. These results suggest that agonist induced change in MLCP activity in smooth muscle is concertedly regulated by RhoA pathway that modulates ROCK and Rac1 pathway that regulates MYPT1/CPI-17 phosphatases. Vertebrate smooth muscle contraction is regulated by phosphorylation of the myosin regulatory light chains. EM studies of smooth muscle myosin molecules suggest that in the dephosphorylated state, activity is switched off by asymmetric interactions between the two myosin heads, in which the ''blocked'' head is thought to be unable to bind to actin, while the ''free'' head has its ATPase activity inhibited. Comparative sequence analysis and molecular modeling suggest that the head interaction may be stabilized by charge attraction between D748 in the converter domain of the free head and K368 of the blocked head, and between R406 or K416 of the blocked head and E169 of the free head (Jung et al., MBC, 2008). To test these possibilities, we investigated the structure of expressed smooth muscle myosin and heavy meromyosin in which the charges at some of these sites was neutralized or reversed. While most of the mutants showed no obvious change in structure compared with wild type, HMM with charge reversal at both 368 and 406 showed fewer molecules with interacting heads when observed by metal shadowing. This was supported by a decrease in sedimentation coefficient (determined by analytical ultracentrifugation) and an increase in actin-activated ATPase activity of the mutant. Whole myosin with the same mutations formed filaments more readily than wild type, also consistent with these results. These observations suggest that charge interactions involving K368 and R406 play a role in stabilizing the head-head interaction of the inactive state. Interestingly, mutation of R403 in cardiac myosin (R406 in smooth muscle) increases motor activity of myosin and causes familial hypertrophic cardiomyopathy. Our results suggest that this could be in part a result of changes in head interaction. We are using fluorescence microscopy to characterize the interaction of single active MLCK molecules with smooth muscle myosin (SMM) filaments and acto-SMM bundles in an in vitro: model system to determine the mechanism by which MLCK phosphorylates SMM. Since ATP is required for the SMM ATPase and the MLCK kinase activity, this requires unphosphorylated SMM filaments that are stable in the presence of ATP, a condition that normally causes disassembly. We have prepared and characterized modified SMM filaments for this study. They are 1) covalently labeled with NHS-Rhodamine for ease of imaging, 2) lightly cross-linked with EDC on the heavy chain so they are stable to ATP-induced disassembly, 3) similar to native SMM filaments in length, 4) fully regulated by phosphorylation measured by acto-SMM ATPase activity, and the ability to move actin in an in vitro motility assay, and 5) able to dissociate from actin in an [ATP]-dependent manner. Interestingly, these modified SMM filaments are capable of bundling actin filaments in the presence of ATP, calmodulin (CaM), and Ca 2þ ; conditions that are sufficient for MLCK to phosphorylate SMM. SMM filaments preferentially bind to actin bundles rather than single actin filaments, and as ATP is titrated into a preparation of acto-SMM bundles, they dissociate leaving short actin filaments which are predominantly bound to SMM filaments. We have imaged the interaction of single quantum dot-labeled MLCK (QD-MLCK) molecules with these SMM filaments and acto-SMM bundles using total internal reflection fluorescence (TIRF) microscopy to visualize single QD-MLCK. We observed QD-MLCK colocalizing with SMM filaments and acto-SMM bundles and will characterize the QD-MLCK interaction with both proteins in the presence of ATP before and after activation of MLCK by Ca 2þ -CaM.
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